---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-168975"
form_type: "8-K"
ticker: null
cik: "0001597553"
company_name: "Sage Therapeutics, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:44:08.499432+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Sage Therapeutics stockholders approve ESPP share increase and bylaw amendments at annual meeting

## Summary
- Stockholders approved 500,000-share increase to the 2014 ESPP, effective immediately.
- Bylaws amended to add universal proxy rules, emergency provisions, and technical updates.
- Directors elected: Michael F. Cola, Barry E. Greene, Jeffrey M. Jonas, M.D., Jessica J. Federer as Class III.
- Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year ending Dec 31, 2023.
- Advisory vote on executive compensation passed with 39,995,146 for (77.5%) vs 11,173,607 against.

## SEC filing metadata
- accession: 0001193125-23-168975
- form_type: 8-K
- cik: 0001597553
- company_name: Sage Therapeutics, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/d522465d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-168975
- JSON: https://secwatch.observer/filing/0001193125-23-168975.json
- Plain text: https://secwatch.observer/filing/0001193125-23-168975.txt

## Key facts
- Governance Changes
  Sage Therapeutics, Inc.: Amended and restated bylaws to eliminate requirement for stockholder list at meetings, address technical failures in remote meetings, add emergency bylaws, and revise director nomination procedures under universal proxy rules (effective 2023-06-15).
  - Change: bylaw amendment
  - Effective: 2023-06-15
  source text: On June 15, 2023, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, as amended (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm
- Shareholder Votes
  Sage Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation.
  - Proposal: say on pay
  - Outcome: passed
  source text: A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm
- Shareholder Votes
  Sage Therapeutics, Inc. shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-31
  source text: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023, was ratified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm
- Shareholder Votes
  Sage Therapeutics, Inc. shareholders approved Amendment to 2014 ESPP to increase authorized shares by 500,000.
  - Proposal: equity plan
  - Outcome: passed
  source text: The amendment to the 2014 ESPP to increase the number of shares of the Company’s common stock authorized for issuance thereunder by 500,000 shares was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm
- Shareholder Votes
  Sage Therapeutics, Inc. shareholders approved Election of four Class III directors.
  - Proposal: director election
  - Outcome: passed
  source text: The following nominees were elected to the Company’s Board as Class III directors for terms expiring at the 2026 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1597553/000119312523168975/0001193125-23-168975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.